UPDATE 1-FDA staff finds Intercept's liver drug effective as monotherapy
April 5 (Reuters) - U.S. Food and Drug Administration staff members on Tuesday supported the use of Intercept Pharmaceuticals Inc's liver drug as a monotherapy in patients unresponsive to standard-of-care.
No comments:
Post a Comment